As more effective treatments for desmoid tumors become available, a critical unmet need is emerging: knowing when to stop therapy. Future research must focus on identifying signals, such as radiologic changes on MRI, to guide treatment duration. This will help clinicians avoid both the risk of early relapse from stopping too soon and the toxicity of unnecessary overtreatment.

For desmoid tumors, systemic therapy is typically paused after 1 to 1.5 years once the tumor stabilizes and stops shrinking. Unlike many other treatments, it can be stopped abruptly without needing to taper the dose, simplifying the discontinuation process for patients and clinicians.

Desmoid tumors exhibit highly variable behavior, acting as a chronic disease in some patients while being manageable in others. This necessitates a personalized, long-term treatment strategy rather than a standard protocol, often requiring a diverse armamentarium of therapeutic options to be used over a patient's lifetime as needs change.

The standard of care for desmoid tumors has shifted away from upfront surgery due to high recurrence rates and poor patient outcomes. Experts now recommend systemic or other local therapies first, reserving surgery only for emergencies or after careful multidisciplinary team review.

In patients with the genetic syndrome FAP, surgery for mesenteric desmoids is strongly contraindicated. The wound healing process itself is believed to initiate tumor growth, making surgery a potential cause, not a cure, unless for an anatomical emergency.

Unlike traditional oncology where the goal is complete eradication, stable residual masses on imaging after successful desmoid tumor treatment are common and acceptable. Clinicians should not be compelled to operate or change therapy based on this finding alone, as it does not indicate active disease.

Surgical resection of desmoid tumors is now discouraged due to the risk of multifocal recurrence. A case demonstrated a patient developing multiple tumors throughout her leg 10 years after an initial surgery, illustrating how the tumor's finger-like growth can lead to widespread seeding if disturbed.

Treatment algorithms for desmoid tumors are highly dependent on tumor location. While medical therapy is preferred for mesenteric or head and neck tumors to avoid morbidity, surgery remains a viable first-line option for the specific case of abdominal wall tumors.

Because up to 20% of desmoid tumors regress on their own, the standard of care for patients with non-critical tumors is to "watch and wait" for 1-2 years. This approach avoids unnecessary treatment and allows physicians to observe the tumor's natural history.